NIDDK Exploratory Clinical Trials for Small Business (R44)

The summary for the NIDDK Exploratory Clinical Trials for Small Business (R44) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

NIDDK Exploratory Clinical Trials for Small Business (R44): The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies. The purpose of this Funding Opportunity Announcement (FOA) is to provide a vehicle for Small Business Concerns (SBCs) submitting Small Business Innovation Research (SBIR) grant applications for investigator-initiated exploratory clinical trials to the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The projects must focus on products related to the mission and goals of the NIDDK and may evaluate drugs, biologics, or devices, as well as surgical, behavioral or rehabilitation therapies.

Federal Grant Title:	NIDDK Exploratory Clinical Trials for Small Business (R44)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Food and Nutrition Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	PAR-17-034
Type of Funding:	Grant
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	September 5th, 2019
Original Application Deadline:	September 5th, 2019
Posted Date:	October 27th, 2016
Creation Date:	October 27th, 2016
Archive Date:	October 6th, 2019
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	October 27th, 2016

Applicants Eligible for this Grant: Small businesses
Additional Information on Eligibility: Other Eligible Applicants include the following: Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, may be allowed. See FOA for Eligibility details
Link to Full Grant Announcement: http://grants.nih.gov/grants/guide/pa-files/PAR-17-034.html
Grant Announcement Contact: NIH OER Webmaster
FBOWebmaster@OD.NIH.GOV

If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster
Similar Government Grants: • Understanding the Functional Contributions and Mechanisms of Type 2 Diabetes Disease-assoc...; • Limited Competition for the Accelerating Medicines Partnership (AMP) in Type 2 Diabetes Kn...; • NIDDK Hematology Central Coordinating Center (U24 Clinical Trial Not Allowed); • Bioinformatics Interdisciplinary Postdoctoral Fellowship in Diabetes, Endocrinology and Me...; • Bioinformatics Interdisciplinary Predoctoral Fellowship in Diabetes, Endocrinology and Met...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Accelerating Discovery of Efficacious Pre-erythrocytic Stage Malaria Vaccines (U01 Clinica...; • Understanding Phage Biology to Support the Development of Bacteriophage Therapy (R21 Clini...; • Strategies to Improve Health Outcomes and to Reduce Disparities in Rural Populations (R01 ...; • Sustained Release of Antivirals for Treatment or Prevention of HIV (SRATP) (R01 Clinical T...; • Organotypic Culture Models developed from Experimental Animals for Chemical Toxicity Scree...